At LabCentral, we recognize the critical importance of making connections, especially during the startup phase of biotech ventures. By fostering collaboration and community among scientists, founders, venture capitalists, sponsors, neighbors, and industry leaders, we provide essential support networks for emerging biotech startups. Our diverse events create opportunities for positive collisions, where ideas converge and flourish, enabling startups to forge partnerships, access resources, and accelerate innovation.
2023 ANNUAL IMPACT REPORT
Community + Partnerships
Resident Success
128
Introductions made between potential investors, partners, and resident companies
81
Executives from resident companies across all 6 facilities participated in Resident Success programming
45
VC firms in attendance across all locations
"LabCentral is not just a facility; it's a dynamic, nurturing ecosystem that propels forward-thinking companies, and being a resident signals credibility to many in the biotech space. For ECI Therapeutics, LabCentral is more than a location; it's our strategic partner and our supporter. It’s a springboard for our vision and our momentum."
CEO of ECI Therapeutics
Golden Tickets
Golden Tickets represent the unique opportunity for our sponsors to directly partner with promising early-stage companies by underwriting the cost of residency for one scientist and one lab bench for one year at LabCentral's 700 Main Street facility.
20
Total Golden Tickets awarded
$1M
Worth of lab space at LabCentral
2023 Resident & Alumni Spotlight
Revolutionizing Rare Disease Therapy
Caraway TX is pursuing innovative approaches for the treatment of genetically defined neurodegenerative and rare diseases.
SPOTLIGHT:
610M Biobucks Deal–Merck to Acquire Caraway Therapeutics, Inc.
Transforming Immuno-Oncology
NextPoint TX programs aim to target the novel HHLA2 pathway, activating anti-tumor immune responses to locate and eradicate cancer cells.
SPOTLIGHT:
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
tRNA Breakthrough
Tevard is developing novel tRNA-based therapies for Duchenne muscular dystrophy.
SPOTLIGHT:
4-year global research collaboration with Vertex Pharmaceuticals–Tevard Biosciences announces collaboration with Vertex to develop novel tRNA-based therapies for Duchenne muscular dystrophy
Key Event Statistics
350+
Events
13,000
Event attendees
1/3
Of events were sponsored
Event Snapshots
Event Highlights
- 1st Annual Partnership Summit
- 1st Annual "What's Next?" Leadership Summit
- Bayer Co.Lab Grand Opening
- 2nd Annual LabCentral Ignite bioDiversity Summit & Awards
- Eli Lilly Science Day
- LUMINESCENCE: bioDiversity at Night
- Game Show: A LabCentral Holiday Party
- Johnson & Johnson / LabCentral 10 Year
- 3rd Annual Cultural Celebration
Thank You to our Sponsors
×